Furosemide plus albumin
PreclinicalSmall molecule
Furosemide plus albumin is one of 10 small molecule programs targeting Critically Ill Patients. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Critically Ill Patients
#DrugCompanyPhaseTrials
1Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Depo-Testosterone
AAzurity Pharmaceuticals
Approved
Treatment With CAZ-AVI
SSoutheast University, China
Phase 3
Prostigmin
Merck & Co.Preclinical
Albumin
LLaboratoire français de Fractionnement et de Biotechnologies
Preclinical
Magnesium
SSpherium Biomed
Preclinical
Fufang E'jiao Jiang
XXiyuan Hospital of China Academy of Chinese Medical Sciences
Preclinical
Degludec Insulin
Sunshine Lake Pharma Co., Ltd.Preclinical
Furosemide plus albumin
JJose J Zaragoza, MD MSc
Preclinical
Beta-Lactams
NNational Taiwan University Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Furosemide plus albumin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- JJose J Zaragoza, MD MSc